$30.62
1.19%
Nasdaq, Aug 29, 10:00 pm CET

Amphastar Pharmaceuticals Inc Stock price

$30.62
+8.95 41.30% 1M
+2.19 7.70% 6M
-6.51 17.53% YTD
-18.24 37.33% 1Y
+0.20 0.66% 3Y
+10.24 50.25% 5Y
+17.75 137.92% 10Y
+21.87 249.94% 20Y
Nasdaq, Closing price Fri, Aug 29 2025
+0.36 1.19%

Key metrics

Basic
Market capitalization
$1.4b
Enterprise Value
$1.8b
Net debt
$376.9m
Cash
$231.8m
Shares outstanding
46.5m
Valuation (TTM | estimate)
P/E
11.0 | 9.0
P/S
2.0 | 1.9
EV/Sales
2.5 | 2.4
EV/FCF
16.4
P/B
1.9
Financial Health
Equity Ratio
46.4%
Return on Equity
21.8%
ROCE
12.6%
ROIC
11.3%
Debt/Equity
0.8
Financials (TTM | estimate)
Revenue
$722.7m | $739.7m
EBITDA
$195.4m | $254.4m
EBIT
$181.7m | $219.6m
Net Income
$134.7m | $158.6m
Free Cash Flow
$109.9m
Growth (TTM | estimate)
Revenue
1.4% | 1.1%
EBITDA
-18.9% | 16.7%
EBIT
-21.0% | 6.9%
Net Income
-19.1% | -0.6%
Free Cash Flow
-38.3%
Margin (TTM | estimate)
Gross
49.9%
EBITDA
27.0% | 34.4%
EBIT
25.1%
Net
18.6% | 21.4%
Free Cash Flow
15.2%
More
EPS
$2.8
FCF per Share
$2.4
Short interest
17.9%
Employees
2k
Rev per Employee
$360.0k
Show more

Is Amphastar Pharmaceuticals Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,011 stocks worldwide.

Amphastar Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

7x Buy
58%
5x Hold
42%

Analyst Opinions

12 Analysts have issued a Amphastar Pharmaceuticals Inc forecast:

Buy
58%
Hold
42%

Financial data from Amphastar Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
723 723
1% 1%
100%
- Direct Costs 362 362
12% 12%
50%
360 360
8% 8%
50%
- Selling and Administrative Expenses 99 99
13% 13%
14%
- Research and Development Expense 66 66
8% 8%
9%
195 195
19% 19%
27%
- Depreciation and Amortization 14 14
25% 25%
2%
EBIT (Operating Income) EBIT 182 182
21% 21%
25%
Net Profit 135 135
19% 19%
19%

In millions USD.

Don't miss a Thing! We will send you all news about Amphastar Pharmaceuticals Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Amphastar Pharmaceuticals Inc Stock News

Neutral
Accesswire
5 days ago
RANCHO CUCAMONGA, CA / ACCESS Newswire / August 28, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, CFO and Dan Dischner, SVP of Corp. Communication, will be participating in an Analyst-Moderated fireside chat at the 2025 Wells Fargo Healthcare Conference on Wednesday, September 3rd, 2025, at 12:45 pm ET. For access, visit Amphastar's Pharmaceuticals websi...
Neutral
Accesswire
21 days ago
Agreement strengthens proprietary peptide pipeline targeting high-value oncology and ophthalmology indications RANCHO CUCAMONGA, CA / ACCESS Newswire / August 12, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar"), a biopharmaceutical company focused on developing, manufacturing, and marketing complex generic and proprietary injectable, inhalation, and intranasal products, today...
Neutral
Accesswire
22 days ago
According to the FDA, Amphastar's iron sucrose injection meets the criteria for bioequivalence and therapeutic equivalence to Venofer ® for the treatment of iron deficiency anemia in patients with chronic kidney disease RANCHO CUCAMONGA, CA / ACCESS Newswire / August 11, 2025 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH), a biopharmaceutical company focused on developing, manufacturing, and m...
More Amphastar Pharmaceuticals Inc News

Company Profile

Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.

Head office United States
CEO Yong Zhang
Employees 2,028
Founded 1996
Website amphastar.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today